留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码
x

肝脏局灶性病变的超声造影现状：SonoVue与Sonazoid的应用对比

冯林林,  刘慧,  李明星,  侯超

downloadPDF
文章导航 > 分子影像学杂志  > 2023 >  46(5): 942-947
冯林林, 刘慧, 李明星, 侯超. 肝脏局灶性病变的超声造影现状：SonoVue与Sonazoid的应用对比[J]. 分子影像学杂志, 2023, 46(5): 942-947. doi: 10.12122/j.issn.1674-4500.2023.05.31
引用本文: 冯林林, 刘慧, 李明星, 侯超. 肝脏局灶性病变的超声造影现状：SonoVue与Sonazoid的应用对比[J]. 分子影像学杂志, 2023, 46(5): 942-947. doi: 10.12122/j.issn.1674-4500.2023.05.31
shu
FENG Linlin, LIU Hui, LI Mingxing, HOU Chao. Current status of contrast-enhanced ultrasound in focal liver lesions: application of SonoVue versus Sonazoid[J]. Journal of Molecular Imaging, 2023, 46(5): 942-947. doi: 10.12122/j.issn.1674-4500.2023.05.31
Citation: FENG Linlin, LIU Hui, LI Mingxing, HOU Chao. Current status of contrast-enhanced ultrasound in focal liver lesions: application of SonoVue versus Sonazoid[J]. Journal of Molecular Imaging, 2023, 46(5): 942-947. doi: 10.12122/j.issn.1674-4500.2023.05.31
shu

肝脏局灶性病变的超声造影现状：SonoVue与Sonazoid的应用对比

doi: 10.12122/j.issn.1674-4500.2023.05.31
  • 1.

    西南医科大学医学影像系，四川 泸州 646000

  • 2.

    西南医科大学附属医院超声医学科，四川 泸州 646000

基金项目: 

四川省医学会项目 Q21089

四川省大学生创新创业项目 S202310632255

详细信息
    作者简介:

    冯林林，在读本科生，E-mail: 1349104492@qq.com

    通讯作者:

    侯超，硕士，主治医师，E-mail: houcdoctor@163.com

Current status of contrast-enhanced ultrasound in focal liver lesions: application of SonoVue versus Sonazoid

  • 1.

    Department of Medical Imaging, Southwest Medical University, Luzhou 646000, China

  • 2.

    Department of Ultrasound, the Affiliated Hospital of Southwest Medical University, Luzhou 646000, China

    摘要
  • 摘要: 超声造影对肝脏占位性病变的诊断能力与CT和MRI相当。目前，SonoVue和Sonazoid是两种常用造影剂，前者是纯血池造影剂，后者在肝脏三血管相的基础上增加了Kupffer相，但二者在肝脏占位性病变的表现的超声造影表现及应用价值是否相同目前尚未见系统报道。本文从SonoVue和Sonazoid的理化性质、二者在肝脏良恶性占位性病变的诊断与鉴别诊断价值、引导介入治疗及安全性能等方面的应用进展进行综述。

     

    Abstract: Contrast-enhanced ultrasound is comparable to CT and MRI in its ability to diagnose focal liver lesions. Currently, SonoVue and Sonazoid were the commonly used contrast agents applied to focal liver lesions, the former being a pure blood pool agent and the latter adding a Kupffer phase to liver's triple-vessel phase, but whether the ultrasonographic feature and application value of the two agents are equivalent has not been reported systemically. This article reviews the progress of the SonoVue and Sonazoid application in terms of their physicochemical properties, the diagnostic and differential diagnostic values in the diagnosis of benign and malignant lesions in the liver, guiding interventional treatment and safety performance.

     

    • HTML全文
    • 参考文献(61)
  • [1] Rumgay H, Arnold M, Ferlay J, et al. Global burden of primary liver cancer in 2020 and predictions to 2040[J]. J Hepatol, 2022, 77 (6): 1598-606. doi: 10.1016/j.jhep.2022.08.021
    [2] Huang DQ, Mathurin P, Cortez-Pinto H, et al. Global epidemiology of alcohol-associated cirrhosis and HCC: trends, projections and risk factors[J]. Nat Rev Gastroenterol Hepatol, 2023, 20(1): 37-49. doi: 10.1038/s41575-022-00688-6
    [3] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020[J]. CA Cancer J Clin, 2020, 70(1): 7-30. doi: 10.3322/caac.21590
    [4] Schwarze V, Rübenthaler J, Marschner C, et al. Advanced fusion imaging and contrast-enhanced imaging (CT/MRI-CEUS) in oncology[J]. Cancers (Basel), 2020, 12(10): 2821. doi: 10.3390/cancers12102821
    [5] 思会, 郭玲玲. 超声造影在鉴别肝脏良、恶性局灶性病变中的应用[J]. 锦州医科大学学报, 2022, 43(3): 76-9. https://www.cnki.com.cn/Article/CJFDTOTAL-JZYX202203016.htm
    [6] Atri M, Jang HJ, Kim TK, et al. Contrast-enhanced US of the liver and kidney: a problem-solving modality[J]. Radiology, 2022, 303 (1): 11-25. doi: 10.1148/radiol.211347
    [7] Yang J, Jiang HY, Xie KL, et al. Profiling hepatocellular carcinoma aggressiveness with contrast-enhanced ultrasound and gadoxetate disodium-enhanced MRI: an intra-individual comparative study based on the Liver Imaging Reporting and Data System[J]. Eur J Radiol, 2022, 154: 110397. doi: 10.1016/j.ejrad.2022.110397
    [8] Wu ML, Li L, Wang JH, et al. Contrast-enhanced US for characterization of focal liver lesions: a comprehensive meta- analysis[J]. Eur Radiol, 2018, 28(5): 2077-88. doi: 10.1007/s00330-017-5152-x
    [9] 袁在贤, 王爱琴, 丁明跃, 等. 医学超声造影剂研究进展[J]. 北京生物医学工程, 2010, 29(6): 650-4. https://www.cnki.com.cn/Article/CJFDTOTAL-BJSC201006029.htm
    [10] 于柠, 马静. 声诺维超声造影剂在肝脏肿瘤诊断中的应用及护理干预[J]. 临床研究, 2021, 29(6): 165-7. https://www.cnki.com.cn/Article/CJFDTOTAL-LCYN202106086.htm
    [11] Takahashi H, Sugimoto K, Kamiyama N, et al. Noninvasive diagnosis of hepatocellular carcinoma on sonazoid-enhanced US: value of the kupffer phase[J]. Diagnostics (Basel), 2022, 12(1): 141. doi: 10.3390/diagnostics12010141
    [12] Zhai HY, Liang P, Yu J, et al. Comparison of sonazoid and SonoVue in the diagnosis of focal liver lesions: a preliminary study[J]. J Ultrasound Med, 2019, 38(9): 2417-25. doi: 10.1002/jum.14940
    [13] Huang JY, Gao L, Li JW, et al. Head-to-head comparison of Sonazoid and SonoVue in the diagnosis of hepatocellular carcinoma for patients at high risk[J]. Front Oncol, 2023, 13: 1-10.
    [14] Kotopoulis S, Popa M, Safont MM, et al. SonoVue® vs. sonazoidTM vs. optisonTM: which bubble is best for low-intensity sonoporation of pancreatic ductal adenocarcinoma?[J]. Pharmaceutics, 2022, 14(1): 98. doi: 10.3390/pharmaceutics14010098
    [15] 朱天彤, 黄瑛. Sonazoid超声造影剂在肝脏肿瘤诊疗中的应用[J]. 现代肿瘤医学, 2020, 28(20): 3624-7. doi: 10.3969/j.issn.1672-4992.2020.20.035
    [16] 何蒙娜, 姜玉新, 吕珂. 超声造影剂Sonazoid与SonoVue的物理特征及临床特点比较[J]. 中国医学影像技术, 2015, 31(2): 306-9. doi: 10.13929/j.1003-3289.2015.02.041
    [17] 张雨, 袁琳, 丁炎, 等. SonoVue与Sonazoid在肝脏局灶性病变中的应用价值对比研究[J]. 南京医科大学学报: 自然科学版, 2022, 42(8): 1159-64. https://www.cnki.com.cn/Article/CJFDTOTAL-NJYK202208017.htm
    [18] 闻晶晶, 沈海云, 孔文韬. 超声造影引导下经皮肝穿刺活检对肝脏局灶性病变的诊断价值[J]. 临床超声医学杂志, 2022, 24(4): 313-5. https://www.cnki.com.cn/Article/CJFDTOTAL-LCCY202204018.htm
    [19] 王学军, 胡晟, 陈轶晖, 等. 肝血管瘤治疗研究进展[J]. 现代医药卫生, 2022, 38(16): 2808-13. doi: 10.3969/j.issn.1009-5519.2022.16.024
    [20] 朱正, 倪庆丰. 超声造影鉴别肝血管瘤的优势分析[J]. 世界最新医学信息文摘, 2017, 17(98): 135-6. doi: 10.19613/j.cnki.1671-3141.2017.98.117
    [21] Sugimoto K, Moriyasu F, Saito K, et al. Kupffer-phase findings of hepatic hemangiomas in contrast-enhanced ultrasound with sonazoid[J]. Ultrasound Med Biol, 2014, 40(6): 1089-95. doi: 10.1016/j.ultrasmedbio.2013.12.019
    [22] Vidili G, Piscaglia F, Ainora ME, et al. Focal nodular hyperplasia: new findings at Doppler ultrasonography[J]. Eur Rev Med Pharmacol Sci, 2020, 24(23): 12288-95.
    [23] Denis de Senneville B, Frulio N, Laumonier H, et al. Liver contrast-enhanced sonography: computer- assisted differentiation between focal nodular hyperplasia and inflammatory hepatocellular adenoma by reference to microbubble transport patterns[J]. Eur Radiol, 2020, 30(5): 2995-3003. doi: 10.1007/s00330-019-06566-1
    [24] He MN, Zhu L, Huang M, et al. Comparison between SonoVue and sonazoid contrast-enhanced ultrasound in characterization of focal nodular hyperplasia smaller than 3 cm[J]. J Ultrasound Med, 2021, 40(10): 2095-104. doi: 10.1002/jum.15589
    [25] Wang W, Chen LD, Lu MD, et al. Contrast-enhanced ultrasound features of histologically proven focal nodular hyperplasia: diagnostic performance compared with contrast- enhanced CT[J]. Eur Radiol, 2013, 23(9): 2546-54. doi: 10.1007/s00330-013-2849-3
    [26] Zhang XY, Tang SS, Huang LP, et al. Contrast-enhanced sonographic characteristics of hepatic inflammatory pseudotumors[J]. J Ultrasound Med, 2016, 35(9): 2039-47. doi: 10.7863/ultra.15.10057
    [27] Kong WT, Wang WP, Shen HY, et al. Hepatic inflammatory pseudotumor mimicking malignancy: the value of differential diagnosis on contrast enhanced ultrasound[J]. Med Ultrason, 2021, 23(1): 15-21. doi: 10.11152/mu-2542
    [28] Saito M, Seo Y, Yano Y, et al. Sonazoid-enhanced ultrasonography and Ga-EOB-DTPA-enhanced MRI of hepatic inflammatory pseudotumor: a case report[J]. Intern Med, 2012, 51(7): 723-6. doi: 10.2169/internalmedicine.51.6811
    [29] Liao MT, Wang CS, Zhang B, et al. Distinguishing hepatocellular carcinoma from hepatic inflammatory pseudotumor using a nomogram based on contrast-enhanced ultrasound[J]. Front Oncol, 2021, 11: 737099. doi: 10.3389/fonc.2021.737099
    [30] Luo P, Wu SY, Yu YL, et al. Current status and perspective biomarkers in AFP negative HCC: towards screening for and diagnosing hepatocellular carcinoma at an earlier stage[J]. Pathol Oncol Res, 2020, 26(2): 599-603. doi: 10.1007/s12253-019-00585-5
    [31] Barr RG, Huang PT, Luo Y, et al. Contrast-enhanced ultrasound imaging of the liver: a review of the clinical evidence for SonoVue and Sonazoid[J]. Abdom Radiol (NY), 2020, 45(11): 3779-88. doi: 10.1007/s00261-020-02573-9
    [32] Kang HJ, Lee JM, Yoon JH, et al. Contrast-enhanced US with sulfur hexafluoride and perfluorobutane for the diagnosis of hepatocellular carcinoma in individuals with high risk[J]. Radiology, 2020, 297(1): E241. doi: 10.1148/radiol.2020209017
    [33] Kunishi Y, Numata K, Morimoto M, et al. Efficacy of fusion imaging combining sonography and hepatobiliary phase MRI with Gd-EOB-DTPA to detect small hepatocellular carcinoma[J]. Am J Roentgenol, 2012, 198(1): 106-14.
    [34] Goto E, Masuzaki R, Tateishi R, et al. Value of post-vascular phase (Kupffer imaging) by contrast- enhanced ultrasonography using Sonazoid in the detection of hepatocellular carcinoma[J]. J Gastroenterol, 2012, 47(4): 477-85.
    [35] 顾炯辉, 何蒙娜, 许敏, 等. 基于时间-强度曲线评价SonoVue和Sonazoid在肝癌中的价值[J]. 中国超声医学杂志, 2020, 36(12): 1133-6. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGCY202012020.htm
    [36] Kang HJ, Lee JM, Yoon JH, et al. SonazoidTM versus SonoVue® for diagnosing hepatocellular carcinoma using contrast- enhanced ultrasound in At-risk individuals: a prospective, single-center, intraindividual, noninferiority study[J]. Korean J Radiol, 2022, 23 (11): 1067-77.
    [37] Khan SA, Tavolari S, Brandi G. Cholangiocarcinoma: Epidemiology and risk factors[J]. Liver Int, 2019, 39(Suppl 1): 19-31.
    [38] Schaarschmidt BM, Kloeckner R, Dertnig T, et al. Real-life experience in the treatment of intrahepatic cholangiocarcinoma by 90Y radioembolization: a multicenter retrospective study[J]. J Nucl Med, 2023, 64(4): 529-35.
    [39] Barner-Rasmussen N, Pukkala E, Hadkhale K, et al. Risk factors, epidemiology and prognosis of cholangiocarcinoma in Finland[J]. United European Gastroenterol J, 2021, 9(10): 1128-35.
    [40] Chen YL, Zhu YL, Chen KL, et al. Differentiation between hepatocellular carcinoma and intrahepatic cholangiocarcinoma using contrast-enhanced ultrasound: a systematic review and metaanalysis[J]. Clin Hemorheol Microcirc, 2021, 79(2): 293-309.
    [41] Huang JY, Li JW, Ling WW, et al. Can contrast enhanced ultrasound differentiate intrahepatic cholangiocarcinoma from hepatocellular carcinoma?[J]. World J Gastroenterol, 2020, 26(27): 3938-51.
    [42] Seo N, Kim DY, Choi JY. Cross-sectional imaging of intrahepatic cholangiocarcinoma: development, growth, spread, and prognosis [J]. Am J Roentgenol, 2017, 209(2): W64-75.
    [43] 张少飞, 张凯, 土继政, 等. 肝内胆管细胞癌超声造影和增强CT增强特征的对比研究[J]. 中国临床医学影像杂志, 2022, 33(2): 114-7. https://www.cnki.com.cn/Article/CJFDTOTAL-LYYX202202009.htm
    [44] Lu Y, Liu BX, Zheng YL, et al. Application of real-time threedimensional contrast-enhanced ultrasound using SonoVue for the evaluation of focal liver lesions: a prospective single-center study [J]. Am J Transl Res, 2018, 10(5): 1469-80.
    [45] Li C, Liu Y, Xu JY, et al. Contrast-enhanced intraoperative ultrasonography with kupffer phase may change treatment strategy of metastatic liver tumors - A single- centre prospective study[J]. Ther Clin Risk Manag, 2021, 17: 789-96.
    [46] Sun LQ, Yin SS, Xing BC, et al. Contrast-enhanced ultrasound with SonoVue and sonazoid for the diagnosis of colorectal liver metastasis after chemotherapy[J]. J Ultrasound Med, 2023, 42(2): 355-62.
    [47] 刘倩, 红华, 李敏, 等. 超声造影参数结合CEA对原发性与转移性肝癌的鉴别诊断价值[J]. 中国超声医学杂志, 2022, 38(7): 790-4. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGCY202207017.htm
    [48] Huang JX, Shi CG, Xu YF, et al. The benefit of contrast-enhanced ultrasound in biopsies for focal liver lesions: a retrospective study of 820 cases[J]. Eur Radiol, 2022, 32(10): 6830-9.
    [49] Wu W, Jing X, Xue GQ, et al. A multicenter randomized controlled study of contrast-enhanced US versus US-guided biopsy of focal liver lesions[J]. Radiology, 2022, 305(3): 721-8.
    [50] 段文斌, 薛蓉, 王子承, 等. 术中Sonazoid超声造影在特殊部位肝细胞癌经腹腔镜微波消融中的应用价值[J]. 中国普通外科杂志, 2022, 31(7): 880-9. https://www.cnki.com.cn/Article/CJFDTOTAL-ZPWZ202207004.htm
    [51] Mukund A, Bansal A, Patidar Y, et al. Role of contrast-enhanced ultrasound with Perfluorobutane in lesion detection, guidance for microwave ablation, and response assessment of hepatocellular carcinoma[J]. Abdom Radiol (NY), 2022, 47(10): 3459-67.
    [52] Nishigori S, Numata K, Irie K, et al. Fusion imaging with contrastenhanced ultrasonography for evaluating the early therapeutic efficacy of radiofrequency ablation for small hypervascular hepatocellular carcinomas with iso-echoic or unclear margins on conventional ultrasonography[J]. J Med Ultrason (2001), 2018, 45 (3): 405-15.
    [53] Jiang B, Han P, Zhu LH, et al. Intraarterial contrast-enhanced ultrasound to predict the short-term tumour response of hepatocellular carcinoma to Transarterial chemoembolization with Lipiodol[J]. BMC Cancer, 2021, 21(1): 1171.
    [54] Faccia M, Garcovich M, Ainora ME, et al. Contrast-enhanced ultrasound for monitoring treatment response in different stages of hepatocellular carcinoma[J]. Cancers (Basel), 2022, 14(3): 481.
    [55] 杨亮, 顾玉明, 鹿皎, 等. 超声造影与增强MRI在评价肝癌TACE术后疗效的应用比较[J]. 介入放射学杂志, 2019, 28(7): 682-6. https://www.cnki.com.cn/Article/CJFDTOTAL-JRFS201907016.htm
    [56] Squires JH, McCarville MB. Contrast-enhanced ultrasound in children: implementation and key diagnostic applications[J]. AJR Am J Roentgenol, 2021, 217(5): 1217-31.
    [57] Shang YN, Xie XY, Luo Y, et al. Safety findings after intravenous administration of sulfur hexafluoride microbubbles to 463, 434 examinations at 24 centers[J]. Eur Radiol, 2023, 33(2): 988-95.
    [58] Dietrich CF, Augustiniene R, Batko T, et al. European federation of societies for ultrasound in medicine andBiology (EFSUMB): an update on the pediatric CEUS registry onBehalf of the "EFSUMB pediatric CEUS registry working group"[J]. Ultraschall Med, 2021, 42(3): 270-7.
    [59] Windrim R, Kingdom J, Jang HJ, et al. Contrast enhanced ultrasound (CEUS) in the prenatal evaluation of suspected invasive placenta percreta[J]. J D'obstetrique Gynecol Du Can, 2016, 38(10): 975-8.
    [60] Xiong X, Yan P, Gao CY, et al. The value of contrast-enhanced ultrasound in the diagnosis of cesarean scar pregnancy[J]. Biomed Res Int, 2016, 2016: 4762785.
    [61] Schwarze V, Marschner C, Negrão de Figueiredo G, et al. Singlecenter study: evaluating the diagnostic performance and safety of contrast-enhanced ultrasound (CEUS) in pregnant women to assess hepatic lesions[J]. Ultraschall Med, 2020, 41(1): 29-35.
    • 相关文章
    • 施引文献
  • 资源附件(0)
  • 加载中
WeChat 点击查看大图
计量
  • 文章访问数:  117
  • HTML全文浏览量:  86
  • PDF下载量:  5
  • 被引次数: 0
出版历程
  • 收稿日期:  2023-05-10
  • 网络出版日期:  2023-10-20
  • 刊出日期:  2023-09-20

目录

    /

    返回文章
    返回
    • 版权所有© 2013《分子影像学杂志》编辑部 ICP备00000000号
    • 重点提示: Adobe Reader6可能造成全文显示不正常，请升级为Adobe Reader7或更高。
    • 地址: 广东省广州市广州大道北1838号 Tel: 020-61648176 E-mail: 

    本系统由 北京仁和汇智信息技术有限公司 开发  技术支持：info@rhhz.net

    x 关闭 永久关闭

    关于《分子影像学杂志》变更刊期通知

    各位专家、作者、读者：

    为了缩短出版时滞，促进科研成果的快速传播，我刊自2024年1月起，刊期由双月刊变更为月刊。本刊主要栏目有：基础研究、临床研究、技术方法、综述等。

    感谢各位专家、作者、读者长期以来对我刊的支持与厚爱！

    南方医科大学学报编辑部

    《分子影像学杂志》

    2023年12月27日